Department of Pediatrics and Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center and Children's Health, Dallas, Texas.
Division of Hematology and Oncology, Cook Children's Medical Center, Fort Worth, Texas.
CA Cancer J Clin. 2021 Jul;71(4):315-332. doi: 10.3322/caac.21665. Epub 2021 Apr 1.
Although significant improvements have been made in the outcomes of children with cancer, the pace of improvement has slowed in recent years as the limits of therapy intensification may have been reached for many pediatric cancers. Furthermore, with increasing numbers of pediatric cancer survivors, the long-term side effects of treatment have become increasingly apparent. Therefore, attention has shifted to the use of molecularly targeted agents and immunotherapies to improve the outcomes of children who are not cured by traditional cytotoxic chemotherapies and to decrease exposure to cytotoxic chemotherapy and reduce late effects. This review describes the recent progress in the treatment of children with cancer, focusing in particular on diseases in which targeted and immunotherapeutic agents have made an impact.
尽管儿童癌症患者的治疗效果有了显著提高,但近年来这一提高速度已经放缓,因为许多儿科癌症的治疗强化可能已经达到了极限。此外,随着儿童癌症幸存者人数的增加,治疗的长期副作用也越来越明显。因此,人们的注意力已经转向使用分子靶向药物和免疫疗法来提高那些无法通过传统细胞毒性化疗治愈的儿童的治疗效果,并减少细胞毒性化疗的暴露,降低迟发性影响。这篇综述描述了儿童癌症治疗的最新进展,特别关注了靶向和免疫治疗药物已经产生影响的疾病。